The role of CRAF in cancer progression: from molecular mechanisms to precision therapies
M Riaud, J Maxwell, I Soria-Bretones… - Nature Reviews …, 2024 - nature.com
The RAF family of kinases includes key activators of the pro-tumourigenic mitogen-activated
protein kinase pathway. Hyperactivation of RAF proteins, particularly BRAF and CRAF …
protein kinase pathway. Hyperactivation of RAF proteins, particularly BRAF and CRAF …
[HTML][HTML] XPO1-dependent nuclear export as a target for cancer therapy
NG Azizian, Y Li - Journal of hematology & oncology, 2020 - Springer
Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large
molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for …
molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for …
Genomic landscape of cell-free DNA in patients with colorectal cancer
Abstract “Liquid biopsy” approaches analyzing cell-free DNA (cfDNA) from the blood of
patients with cancer are increasingly utilized in clinical practice. However, it is not yet known …
patients with cancer are increasingly utilized in clinical practice. However, it is not yet known …
Mutant IDH inhibits IFNγ–TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma
Abstract Isocitrate dehydrogenase 1 mutations (mIDH1) are common in
cholangiocarcinoma.(R)-2-hydroxyglutarate generated by the mIDH1 enzyme inhibits …
cholangiocarcinoma.(R)-2-hydroxyglutarate generated by the mIDH1 enzyme inhibits …
[HTML][HTML] When should we order a next generation sequencing test in a patient with cancer?
R Colomer, R Mondejar, N Romero-Laorden… - …, 2020 - thelancet.com
Technical advances in genome sequencing and the implementation of next-generation
sequencing (NGS) in clinical oncology have paved the way for individualizing cancer patient …
sequencing (NGS) in clinical oncology have paved the way for individualizing cancer patient …
[HTML][HTML] The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer
Background Targeted therapies have transformed clinical management of advanced biliary
tract cancer (BTC). Cell-free DNA (cfDNA) analysis is an attractive approach for cancer …
tract cancer (BTC). Cell-free DNA (cfDNA) analysis is an attractive approach for cancer …
[HTML][HTML] KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition
Lung squamous cell carcinoma (LUSC) represents a major subtype of lung cancer with
limited treatment options. KMT2D is one of the most frequently mutated genes in LUSC (> …
limited treatment options. KMT2D is one of the most frequently mutated genes in LUSC (> …
[HTML][HTML] Racial differences in genomic profiling of prostate cancer
Genetic Alterations in Prostate Cancer Among nearly 2400 men with prostate cancer, next-
generation sequencing of 474 genes showed differences among racial groups in the …
generation sequencing of 474 genes showed differences among racial groups in the …
BRAF—A tumour-agnostic drug target with lineage-specific dependencies
In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …
Combinatorial strategies to target RAS-driven cancers
N Perurena, L Situ, K Cichowski - Nature Reviews Cancer, 2024 - nature.com
Although RAS was formerly considered undruggable, various agents that inhibit RAS or
specific RAS oncoproteins have now been developed. Indeed, the importance of directly …
specific RAS oncoproteins have now been developed. Indeed, the importance of directly …